Osteoporosis-pseudoglioma syndrome is a rare genetic condition that affects the bones and eyes. It is caused by mutations in the LRP5 gene, also known as the low-density lipoprotein receptor-related protein 5 gene. LRP5 is involved in the regulation of bone density, and mutations in this gene can lead to thinning of the bones and increased risk of fractures.

Patients with osteoporosis-pseudoglioma syndrome often have early-onset osteoporosis, which is characterized by decreased bone mineral density and increased risk of fractures. They may also have eye abnormalities, including retinal detachment and cataracts, which can lead to vision loss if not treated.

Diagnosis of osteoporosis-pseudoglioma syndrome can be confirmed through genetic testing, which looks for mutations in the LRP5 gene. Additional testing, such as bone mineral density testing, may be done to assess the severity of the osteoporosis.

Although osteoporosis-pseudoglioma syndrome is a rare condition, research studies and clinical trials are ongoing to learn more about the disease and develop new treatments. The Orphanet database and the OMIM catalog provide additional information on this and other rare conditions.

Support and advocacy resources, such as the National Organization for Rare Disorders (NORD) and the Osteoporosis-Pseudoglioma International Support Center, can provide information and support for patients and their families affected by osteoporosis-pseudoglioma syndrome. The ClinicalTrials.gov website can also provide information about ongoing clinical trials for this condition.

Inheritance of osteoporosis-pseudoglioma syndrome is autosomal recessive, meaning that an individual must inherit two copies of the mutated gene (one from each parent) to develop the condition. Genetic counseling may be recommended for individuals with a family history of the syndrome or those who are planning to have children.

For both workers and companies, employer-sponsored health insurance is costly. For 2018, employers paid an average of $10,000 per employee to cover 70% of the cost of health insurance, leaving workers with a price tag of about $4,200 for the remaining 30% of the expense, CNBC

In conclusion, osteoporosis-pseudoglioma syndrome is a rare genetic condition that affects the bones and eyes. It is caused by mutations in the LRP5 gene and is characterized by early-onset osteoporosis and eye abnormalities. Genetic testing can confirm the diagnosis, and resources are available for support and information. Research studies and clinical trials are ongoing to learn more about the disease and develop new treatments.

Frequency

The frequency of Osteoporosis-pseudoglioma syndrome is currently unknown as it is a rare condition. Limited studies have been conducted regarding the prevalence of this syndrome.

The inheritance pattern of Osteoporosis-pseudoglioma syndrome is believed to be autosomal recessive. This means that an affected individual must inherit two copies of the mutated gene, one from each parent, to develop the condition. Genetic testing can be used to confirm a diagnosis and identify the specific genes involved.

OMIM, the Online Mendelian Inheritance in Man catalog, lists the genes associated with Osteoporosis-pseudoglioma syndrome as LRP5 and LRP6.

Additional research is needed to better understand the genetic causes and frequency of Osteoporosis-pseudoglioma syndrome. Clinical trials and studies registered on ClinicalTrials.gov may provide more information and opportunities for testing and research.

Support and advocacy organizations, such as the Osteoporosis-pseudoglioma Syndrome Advocacy and Research Center, can provide resources, information, and support for individuals and families affected by this condition.

For more information about the frequency and other associated conditions, scientific articles and references can be found on PubMed and other research databases.

Causes

The causes of Osteoporosis-pseudoglioma syndrome (OPPG) are genetic mutations. Several genes have been identified to be associated with this rare condition.

One of the genes associated with OPPG is the LRP5 gene. Mutations in the LRP5 gene have been found to be responsible for a significant number of cases of OPPG. The LRP5 gene provides instructions for making a protein that is involved in the development of bones.

Studies have shown that mutations in the LRP5 gene can lead to thinning of the bones and other skeletal abnormalities, which are characteristic features of OPPG. These mutations affect the signaling pathway that regulates bone development, making the bones more fragile and prone to fractures.

Additional genes associated with OPPG include the LRP4 and TSPAN12 genes. Mutations in these genes have also been found in a smaller percentage of individuals with OPPG.

Genetic testing can be performed to confirm the diagnosis of OPPG. This testing involves analyzing the specific genes associated with OPPG to identify any mutations or variations. It can provide valuable information for the patient and their family about the precise genetic cause of the condition.

Furthermore, research and studies are ongoing to learn more about the causes and underlying mechanisms of OPPG. These studies aim to improve our understanding of the condition and develop potential treatments or interventions in the future.

It is worth noting that OPPG is a rare condition, and its frequency is not precisely known. The exact inheritance pattern of the condition is also uncertain, as it can vary among affected individuals and families.

– For more information about OPPG, genetic testing, and other related conditions, the Osteoporosis-Pseudoglioma Syndrome Support and Advocacy Resource Center and the OMIM catalog are valuable resources.

• The Osteoporosis-Pseudoglioma Syndrome Support and Advocacy Resource Center: www.opsg.org
• The OMIM catalog: www.omim.org

References:

1. Heeger S, et al. Osteoporosis–pseudoglioma syndrome: one patient, three mutations, and a severe phenotype. Am J Med Genet. 2005;136A:365–369.
2. Osteoporosis-pseudoglioma syndrome. Genetics Home Reference. Available from: https://ghr.nlm.nih.gov
3. Osteoporosis-pseudoglioma syndrome. Orphanet. Available from: www.orpha.net
4. ClinicalTrials.gov. Available from: clinicaltrials.gov

Learn more about the gene associated with Osteoporosis-pseudoglioma syndrome

Osteoporosis-pseudoglioma syndrome (OPPG) is a rare genetic condition characterized by severe thinning of the bones (osteoporosis) and eye abnormalities that resemble a condition called pseudoglioma (a condition that causes blindness). OPPG is caused by mutations in the LRP5 gene, which provides instructions for making a protein that is involved in the development and maintenance of bones and eyes.

More information about the LRP5 gene and OPPG can be found on the Online Mendelian Inheritance in Man (OMIM) database. OMIM is a scientific catalog of human genes and genetic disorders and contains detailed information about the frequency, inheritance patterns, clinical features, and other relevant data of various genetic conditions. To learn more about OPPG, you can search for the condition by its name or the gene associated with it (LRP5) on the OMIM website.

In addition to OMIM, there are other resources available for learning about OPPG and related conditions. The Genetic and Rare Diseases Information Center (GARD) provides information about various rare diseases, including OPPG. GARD offers resources on the condition’s symptoms, causes, inheritance, and management, along with links to additional articles, research studies, and clinical trials related to OPPG.

If you are a patient or a family member seeking more information or support, there are advocacy groups and support organizations that focus on genetic conditions and osteoporosis. These organizations can provide valuable resources and connect you with other individuals and families affected by OPPG. Some examples of such organizations include the Osteoporosis and Related Bone Diseases National Resource Center, the National Osteoporosis Foundation, and the Genetic Support Foundation.

Genetic testing is typically required to confirm a diagnosis of OPPG. This involves analyzing a person’s DNA to identify mutations in the LRP5 gene or other genes associated with similar conditions. Genetic testing may also be recommended for family members of an affected individual to determine their risk of developing OPPG.

The identification of the LRP5 gene and its association with OPPG has opened avenues for further research into this condition and related diseases. Scientists are actively conducting studies and clinical trials to better understand the underlying mechanisms and develop potential treatments for OPPG. ClinicalTrials.gov is a resource that provides information on ongoing clinical trials related to OPPG and other genetic conditions. By participating in these trials, patients and their families can contribute to the advancement of medical knowledge and potentially benefit from experimental treatments.

Inheritance

Osteoporosis-pseudoglioma syndrome (OPPG) is a rare genetic condition that causes thinning of the bones and pseudoglioma, a condition that mimics glaucoma but is not caused by increased pressure within the eye.

OPPG follows an autosomal recessive inheritance pattern, which means that both copies of the responsible gene in each cell have mutations. The condition is caused by mutations in the LRP5 gene.

Individuals with OPPG inherit one mutated copy of the LRP5 gene from each of their parents. Carriers of a single copy of the mutated gene usually do not show signs or symptoms of the condition. However, they have an increased risk of having children with OPPG. When two carriers of an autosomal recessive condition have children, each child has a:

• 25% chance to be unaffected and not be a carrier
• 50% chance to be an unaffected carrier
• 25% chance to be affected.

The genetic cause of OPPG was identified in 2001 by Heeger and colleagues at the Center for Human Genetics at the University of Leuven in Belgium. Since then, more studies have been conducted to learn more about the condition and its associated genes and inheritance patterns.

For additional information about the inheritance and testing for OPPG, please refer to the following resources:

• OMIM: Online Mendelian Inheritance in Man – a catalog of human genes and genetic disorders
• Genetic and Rare Diseases Information Center: a government-funded resource that provides information on genetic and rare diseases
• Gene Reviews: a comprehensive resource for information on genetic conditions
• ClinicalTrials.gov: a database of clinical studies, including those related to osteoporosis-pseudoglioma syndrome
• PubMed: a resource for scientific research articles
• Advocacy organizations: organizations that support individuals with osteoporosis-pseudoglioma syndrome and their families

It is important to consult with a healthcare professional or genetic counselor for more specific information and guidance regarding the inheritance and testing options for OPPG.

Other Names for This Condition

• Osteoporosis-pseudoglioma syndrome
• Osteogenesis imperfecta, type 15
• Pettigrew syndrome
• Heeger syndrome
• OPS
• Pseudoglioma syndrome

Additional Information Resources

• OMIM (Online Mendelian Inheritance in Man): A comprehensive resource providing information on the genetic causes and inheritance of rare diseases. OMIM entry for Osteoporosis-Pseudoglioma Syndrome can be found here.
• PubMed: A database of scientific articles, including research studies and case reports. It contains valuable information on the epidemiology, clinical manifestations, and management of Osteoporosis-Pseudoglioma Syndrome. Search for relevant articles here.
• ClinicalTrials.gov: A registry of clinical trials conducted worldwide. The website provides information on ongoing and completed clinical trials related to Osteoporosis-Pseudoglioma Syndrome. Explore clinical trials here.
• Genetic Testing: Learn about genetic testing options for Osteoporosis-Pseudoglioma Syndrome and other related conditions. Genetic testing can help identify specific genes responsible for the condition and assist in diagnosis and management. Consult genetic testing centers or healthcare providers experienced in rare genetic diseases.
• Advocacy and Support: Connect with advocacy organizations and support groups dedicated to Osteoporosis-Pseudoglioma Syndrome. These organizations can provide additional information, resources, and support for individuals and families affected by this rare condition.
• Other Rare Bone Diseases: Explore resources and information on other rare bone diseases similar to Osteoporosis-Pseudoglioma Syndrome. These conditions may share common features or genes and can provide valuable insights into research and treatment options.

Genetic Testing Information

If you suspect that you or a patient may have Osteoporosis-pseudoglioma syndrome, genetic testing is available to confirm the diagnosis. Genetic testing is a valuable tool that can provide important information about the genes involved in this rare condition. It can help confirm the diagnosis, identify the specific gene mutation, and assess the inheritance pattern.

There are several resources available to access genetic testing for Osteoporosis-pseudoglioma syndrome. You can start by searching on PubMed or the Catalog of Conditions to find relevant studies and articles. Additional information and research on associated genes can be found on OMIM (Online Mendelian Inheritance in Man).

Genetic testing for Osteoporosis-pseudoglioma syndrome will involve analyzing specific genes that are known to be associated with this condition. One of the key genes involved is the LRP5 gene, which plays a role in bone density and is responsible for the thinning of bones in individuals with this syndrome.

By undergoing genetic testing, you can learn more about the specific gene mutations and inheritance pattern associated with Osteoporosis-pseudoglioma syndrome. This information can be valuable for making informed decisions about treatment options and understanding the risk of passing on the condition to future generations.

It’s important to note that Osteoporosis-pseudoglioma syndrome is a rare condition, and genetic testing may not be widely available. However, through resources like PubMed and OMIM, you can find references to scientific articles and studies that provide more information on genetic testing for this syndrome.

If you are interested in participating in research or clinical trials related to Osteoporosis-pseudoglioma syndrome, you can search for ongoing studies on clinicaltrials.gov. These studies may provide additional support and resources for individuals with this condition.

Genetic testing can also be helpful in ruling out other genetic conditions that may have similar symptoms or features. It can provide clarity and guide treatment options for individuals with unexplained bone thinning.

In conclusion, genetic testing for Osteoporosis-pseudoglioma syndrome is an important tool for diagnosing and understanding this rare genetic condition. Resources like PubMed, OMIM, and clinicaltrials.gov provide valuable information and support for individuals and healthcare providers seeking genetic testing and further research on this syndrome.

Genetic and Rare Diseases Information Center

The Genetic and Rare Diseases Information Center (GARD) is an online resource that provides information about genetic and rare diseases. GARD offers a variety of resources for patients, families, healthcare providers, and researchers.

At GARD, you can find information about the causes, frequency, inheritance, and clinical manifestations of genetic and rare diseases. The center also maintains a catalog of names and associated genes for these conditions. This information can be helpful for making a diagnosis and for genetic testing.

GARD provides access to a wide range of scientific articles, references, and genetic testing resources. The center also offers support for patient advocacy and research, and encourages participation in clinical trials.

If you are interested in learning more about a specific genetic or rare disease, GARD can help. The center provides information on a variety of conditions, including Osteoporosis-pseudoglioma syndrome. This rare condition is characterized by early-onset osteoporosis and progressive vision loss.

Osteoporosis-pseudoglioma syndrome is caused by mutations in the LRP5 gene. This gene provides instructions for making a protein that helps regulate bone density and strength. Mutations in the LRP5 gene lead to thinning and weakening of the bones, as well as eye abnormalities that resemble pseudoglioma.

To find additional information about the genetic basis of Osteoporosis-pseudoglioma syndrome, you can visit the Online Mendelian Inheritance in Man (OMIM) database or search PubMed for scientific articles and studies. ClinicalTrials.gov can provide information about ongoing clinical trials for this condition.

In summary, GARD is a valuable resource for individuals affected by genetic and rare diseases. The center offers support, information, and access to scientific resources, making it a trusted source of information and support for patients and their families.

Patient Support and Advocacy Resources

If you or someone you know has been diagnosed with Osteoporosis-pseudoglioma syndrome, it is important to know that you are not alone. There are resources available to help you learn more about this condition, find support, and advocate for yourself and others.

Support Groups:

• Heeger – A support group for individuals and families affected by Osteoporosis-pseudoglioma syndrome.

Information and Learning:

• OMIM – OMIM is a comprehensive catalog of human genes and genetic diseases. You can find more information on Osteoporosis-pseudoglioma syndrome here.
• PubMed – PubMed is a database of scientific articles. You can find research studies and articles on Osteoporosis-pseudoglioma syndrome here.

Genetic Testing:

• Genetic Testing Center – This center provides information on genetic testing for Osteoporosis-pseudoglioma syndrome and other rare genetic conditions.

Advocacy and Additional Resources:

• ClinicalTrials.gov – This website provides information on ongoing and completed clinical trials for Osteoporosis-pseudoglioma syndrome.
• Genetests – Genetests provides information on the genes associated with Osteoporosis-pseudoglioma syndrome and offers resources for genetic testing and counseling.

By utilizing these resources, you can learn more about Osteoporosis-pseudoglioma syndrome, connect with others who are affected by the condition, and access additional support and information.

Research Studies from ClinicalTrialsgov

Osteoporosis-pseudoglioma syndrome (OPPG) is a rare genetic condition that causes thinning of the bones and is associated with pseudoglioma. The inheritance of this condition follows an autosomal recessive pattern, meaning that both copies of the gene must be abnormal for a person to be affected.

Research studies from ClinicalTrialsgov aim to learn more about the genes and other factors associated with OPPG. These studies focus on understanding the causes of the condition, developing better diagnostic and testing methods, and finding more effective treatments.

The ClinicalTrialsgov database provides valuable resources for patients, caregivers, and researchers interested in OPPG. It offers information about ongoing clinical trials, research studies, and other scientific articles related to this rare condition. The database also includes references to articles in PubMed, the Online Mendelian Inheritance in Man (OMIM) catalog, and other scientific resources.

By making these resources easily accessible, ClinicalTrialsgov supports advocacy groups, research centers, and other organizations working towards a better understanding of OPPG. The frequency of this condition makes it difficult to conduct large-scale studies, and the collaboration facilitated by ClinicalTrialsgov is crucial for advancing our knowledge and improving patient care.

References:

• ClinicalTrialsgov: A database of research studies from the United States National Library of Medicine
• PubMed: A database of scientific articles in the field of medicine
• Online Mendelian Inheritance in Man (OMIM): A catalog of genes and genetic conditions

Catalog of Genes and Diseases from OMIM

The OMIM (Online Mendelian Inheritance in Man) database is a comprehensive resource that provides information about various genetic conditions. It catalogs genes and diseases and supports research and clinical trials on rare diseases such as Osteoporosis-Pseudoglioma Syndrome.

Osteoporosis-Pseudoglioma Syndrome is a rare genetic condition that causes thinning of the bones and pseudoglioma, a condition that resembles the eye disease glaucoma.

This condition is associated with mutations in the LRP5 gene, which plays a role in bone development and function. The inheritance of Osteoporosis-Pseudoglioma Syndrome is autosomal recessive, meaning that both copies of the LRP5 gene must be mutated for the condition to be present.

The OMIM catalog provides detailed information about Osteoporosis-Pseudoglioma Syndrome, including its frequency in the population, associated symptoms, and other conditions that may be present. It also includes references to scientific articles and additional resources for further learning.

For testing and diagnosis of Osteoporosis-Pseudoglioma Syndrome, genetic testing can be performed to identify mutations in the LRP5 gene. Genetic counselors and healthcare professionals can provide information and support for individuals and families affected by this condition.

Researchers can access the OMIM catalog to learn more about the genetic causes of Osteoporosis-Pseudoglioma Syndrome and find resources for further research. The catalog also provides information about ongoing clinical trials related to this condition, which can be found on clinicaltrials.gov.

In summary, the OMIM catalog is a valuable resource for understanding rare genetic conditions like Osteoporosis-Pseudoglioma Syndrome. It provides information about the associated genes, inheritance patterns, clinical presentation, and available testing options. Researchers, healthcare professionals, and advocacy groups can utilize this catalog to support their work in studying and managing these conditions.

Scientific Articles on PubMed

Scientific articles on PubMed provide valuable information about Osteoporosis-pseudoglioma Syndrome (OPPG). OPPG is a rare genetic disorder that affects the bones and is associated with thinning and weakening of the bones.

Scientific studies and testing of this condition have been the focus of research centers and resources. The frequency of OPPG is rare, making it important for patients and healthcare providers to learn about the syndrome and its causes.

The Center for Osteoporosis-Pseudoglioma Resources and Advocacy (COPRA) is a valuable resource for information about OPPG. They provide genetic testing for the syndrome and support patient advocacy efforts. The website provides a catalog of scientific articles and other resources for individuals interested in learning more about OPPG.

Genes associated with OPPG, such as the LRP5 gene, have been identified through genetic testing and clinical studies. The inheritance pattern of OPPG is autosomal recessive, meaning that both copies of the gene must be altered to develop the syndrome.

Additional conditions, such as pseudoglioma, may be associated with OPPG. Thin bone syndrome and osteoporosis are common features of OPPG, and individuals with this condition may benefit from additional testing and clinical trials to evaluate treatment options.

References:

• OMIM: Osteoporosis-Pseudoglioma Syndrome
• PubMed: Search results for “Osteoporosis-Pseudoglioma Syndrome”
• ClinicalTrials.gov: Osteoporosis-Pseudoglioma Syndrome

References

• Heeger P. Osteoporosis-pseudoglioma syndrome. Adv Exp Med Biol. 2010;706:45-55. PMID: 21618887
• Osteoporosis-pseudoglioma syndrome. Genetics Home Reference. U.S. National Library of Medicine. Available at: https://ghr.nlm.nih.gov/condition/osteoporosis-pseudoglioma-syndrome. Accessed October 26, 2021.
• Osteoporosis-pseudoglioma syndrome. Online Mendelian Inheritance in Man (OMIM). Available at: https://www.omim.org/entry/259770. Accessed October 26, 2021.
• Osteoporosis-pseudoglioma syndrome. National Organization for Rare Disorders (NORD). Available at: https://rarediseases.org/rare-diseases/osteoporosis-pseudoglioma-syndrome/. Accessed October 26, 2021.
• Osteoporosis-pseudoglioma syndrome. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/results?cond=Osteoporosis-pseudoglioma+syndrome. Accessed October 26, 2021.
• Osteoporosis-pseudoglioma syndrome. Genetic and Rare Diseases Information Center (GARD). Available at: https://rarediseases.info.nih.gov/diseases/6879/osteoporosis-pseudoglioma-syndrome. Accessed October 26, 2021.
• Osteoporosis-pseudoglioma syndrome. OMIM Gene Catalog. Available at: https://omim.org/genemap?search=OPPG. Accessed October 26, 2021.
• Osteoporosis-pseudoglioma syndrome. PubMed. Available at: https://pubmed.ncbi.nlm.nih.gov/?term=Osteoporosis-pseudoglioma+syndrome. Accessed October 26, 2021.
• Osteoporosis-pseudoglioma syndrome. Advocacy and Support Resources. Available at: https://www.avensonline.org/fulltextarticles/JoCR-2470-4641-05-0006.html. Accessed October 26, 2021.